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The BAT organ is unique in that it has evolved to safely dissipate large amounts of chemical energy—a quality
that might be harnessed to help humans deal with a dangerously hypercaloric environment and still remain in
good health.Introduction
Cold weather and scarcity of food have accompanied us and
constituted serious threats to our survival for the entire duration
of our species’ history. Fortunately, two tissues have been
selected by nature to help us deal with these difficulties: white
adipose tissue (WAT) and brown adipose tissue (BAT). While
WAT helps us compensate for fluctuating availability of energy,
BAT keeps us warm—at least during our first days of extrauterine
life. As will be discussed, it is most likely of importance to us for
longer than that. It is only very recently that, by having an
adequate food supply and modern housing, we have circum-
vented the problems associated with famine and cold
weather—at least in some parts of the world—and thus become
less dependent on WAT and BAT for our survival. This has
occurred to the extent that new dangers have been created. A
sedentary inactive lifestyle and a wealth of calories have gener-
ated a cluster of obesity-related health problems known as the
metabolic syndrome or syndrome X, which in turn is associated
with a positive energy balance—here BAT can play a role by
increasing energy expenditure. BAT is only present in mammals
and is estimated to have emerged some 150 million years ago.
BAT is unique in the sense that brown adipocytes can uncouple
respiration from ATP synthesis. This is mediated by uncoupling
protein 1 (ucp1), which is uniquely expressed by the mitochon-
drion-rich brown adipocyte. The inward translocation of protons
across the mitochondrial inner membrane by ucp1 is a route of
proton transport that will generate heat and not ATP—a process
known as adaptive or facultative thermogenesis. This mecha-
nism is present and extensively studied in rodents; it is vital for
regulation of body temperature (Enerba¨ck et al., 1997) and is
also of importance for control of body weight (Feldmann et al.,
2009). A role for metabolically active BAT in the normal physi-
ology of healthy adults has been discussed for some time and
recently revisited in a series of investigations applying state-of-
the-art imaging methodology.Evolution of BAT—A Specialized Thermogenic Organ
BAT is highly vascularized and made up of cells with multilocular
lipid droplets. These cells are rich in mitochondria, and they
express ucp1. This enables the BAT organ to produce heat by
uncoupling mitochondrial respiration from ATP production.
This feature is believed to be unique to endothermic placental
mammals, which evolved about 140 million years ago, providing
them with the ability to maintain a body temperature significantly
higher than ambient temperature. Even though ectothermic fish,248 Cell Metabolism 11, April 7, 2010 ª2010 Elsevier Inc.e.g., common carp, have uncoupling activity together with cold-
induced expression of ucp1 (Jastroch et al., 2007), and birds can
probably use avian ucp in much the same way as mammals use
ucp1 to generate heat (Mozo et al., 2005), they both lack BAT.
Recently, it was shown for the first time that cold-induced
expression of ucp1 in BAT also exists outside the lineage of
Eutherian (endothermic placental) mammals—in a single species
of marsupial, the fat-tailed dunnart (Sminthopsis crassicaudata).
This indicates that the BAT organ is older than what was previ-
ously believed and started to develop already in the Therian
(marsupial and Eutherian) lineage (Jastroch et al., 2008). Thus,
the archetypal BAT organ was present at least 150 million years
ago, facilitating life in the cold for early mammals based on its
unique ability to produce heat independently of shivering and
locomotor activity.BAT and Human BAT
Compared to other organs, the BAT organ is a relatively recently
discovered entity. The Swiss naturalist Konrad Gessner pub-
lished the first description of BAT in 1551, but it was not until
the twentieth century that BAT was generally regarded as a histo-
genetically mature and distinct tissue. The earliest unequivocal
report of BAT in humans (which, at the time, was referred to as
the interscapular or hibernating gland) was by Shinkishi Hatai
in 1902, who in his seminal study of BAT in human embryos
stated, ‘‘Much to his surprise, he found in the embryos examined
a gland which corresponded closely in position, general appear-
ance and to some extent in structure, to the hibernating gland of
lower Mammals.’’
The BAT described was located under the sternocleidomas-
toid and trapezius muscles and ran laterally and in parallel with
the neck. Microscopic examination revealed the presence of
cells with ‘‘polygonal lobules’’ and ‘‘. . . an abundant supply of
non-medullated nerve-fibers’’ together with ‘‘. . . an abundant
supply of blood . . .’’—which today still stands as an accurate
morphological description of BAT (Hatai, 1902). In the human
adult, no corresponding structure could be found. Since then,
BAT, in infants and adults, has been investigated in several
necropsy studies (e.g., Heaton, 1972). In the humans, the major
locations of BAT are (1) cervical/axillary, (2) perirenal/adrenal,
and (3) along the large blood vessels and trachea, and as
finger-like projections following the intercostal arteries. In infants
also a thin kite-shaped sheet of BAT between the shoulder
blades has been described (Figure 1). Categories 1 and 2 repre-
sent approximately 50% of the total mass of BAT in infants. With
Figure 1. Location of hBAT in Adults and
Infants
Even though the terminology used to depict the
major hBAT depots is not entirely consistent, the
predominating locations are, based on results
from postmortem and PET/CT studies: (A)
thyroid/tracheal, (B), mediastinal, (C) paracervi-
cal/supraclavicular, (D) parathoracical, (E) supra-
and perirenal. In the infant, also a kite-shaped
thin layer of BAT has been described (in light
brown).
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guishable from WAT. However, based on postmortem morpho-
logical analysis, several investigators have reported that BAT
persists into adulthood in many of the sites at which it occurs
in infancy (Heaton, 1972). It is more common in young subjects,
and some authors have reported that there is more BAT in indi-
viduals exposed to cold environments (Huttunen et al., 1981).
In a study of 52 subjects in eight cohorts ranging from 0–10 to
70–80 years of age, it was observed that with age the number
of depots that were positive for BAT declined. Notably, of the
18 locations examined and found to be positive in the 0–10
year cohort, the neck/interscapular/intercostal regions together
with trachea/pericardium and renal/suprarenal depots (Figure 1)
were the ones that were also positive in higher age cohorts, i.e.,
in 50- to 80-year-olds (Heaton, 1972).
Function of hBAT
That BAT has a role in the development of obesity was sug-
gested some 30 years ago (Himms-Hagen, 1979). A dual role
for the BAT organ has been proposed, apart from thermoregula-
tory thermogenesis that is responding to a cold environment,
that via increased activity in sympathetic nerve endings will
induce ucp1-dependent heat production as well as increased
BAT mass—BAT in rodents has also been shown to increase in
response to ‘‘cafeteria diet’’ (Rothwell and Stock, 1979) and
other so-called recruiting diets. It should be pointed out that
while thermoregulatory thermogenesis is generally accepted,
the biological role of metaboloregulated thermogensis is less
well studied and somewhat more controversial. Metaboloregu-
lated thermogensis has been interpreted as a form of defense
against a caloric load, and also as a way of surviving on dietsCell Metabolismthat are low in essential nutrients without
there being any pronounced effects on
energy depots, since excess energy will
be dissipated by active BAT. Another
possibility is that readily available calories
will signal to increase the BAT compart-
ment—not necessarily for the purpose
of dissipating energy acutely, but rather
to increase its size, since energy appears
to be abundant, which would perhaps
confer an enhanced capacity to adapt
to sudden bursts of cold in the environ-
ment.
Although the first report of BAT was
published more than 450 years ago, its
physiological role as a thermogeniceffector organ regulated by the sympathetic nervous system
was formulated and experimentally supported as late as 1961,
by Robert Smith (Smith, 1961). In a later study using postmortem
or surgical biopsies from perinephric fat depots, the presence of
ucp1 and also norepinephrin-induced oxygen consumption was
noted, whereas any significant contribution to overall energy
expenditure could not be ascertained (Cunningham et al.,
1985). Astrup and coworkers examined the role of human perire-
nal BAT in ephedrine-induced thermogenesis and arrived at the
conclusion that the increase in oxygen consumption observed
was mainly derived from the skeletal muscle and not from BAT
(Astrup et al., 1985). There have, however, been reports of
increased BAT mass with effects on human body weight: for
instance, a case with a large hibernoma in a 24-year-old man.
The tumor measured 8 3 11 3 4.5 cm, and the patient showed
a weight reduction of 6.8 kg over a year (Allegra et al., 1983).
How much of this weight loss was due to increased energy
expenditure was not addressed in the study. Also, in cases
with pheochromocytomas (rare catecholamine-secreting
tumors), there is evidence of increased thermogenically active
BAT mass with the capacity to influence metabolic rate on the
basis of thermogenesis (Lean et al., 1986). It has been estimated
that 40–50 g of maximally stimulated BAT in man could corre-
spond to as much as 20% of energy expenditure, equivalent to
20 kg of body weight, over a year (Rothwell and Stock, 1983).
Thus, even a fraction of this effect could be highly relevant in
terms of human energy expenditure. It should be pointed out
that while in the mouse BAT makes up some 5%–10% of the
total body weight, the corresponding value for infants has been
estimated to be approximately 2%–5% and in adults about
0.05%–0.1%.11, April 7, 2010 ª2010 Elsevier Inc. 249
Figure 2. PET/CT Registration of
FDG-Glucose Uptake Regions
Images of an adult healthy subject that either
spent 2 hr prior to examination in ambient room
temperature (warm) or 2 days later was exposed
to approximately 18C (cold). Cold-induced
FDG-glucose uptake regions are marked with
white arrows; biopsies of these regions confirmed
BAT identity (from Virtanen et al., 2009; with
permission from The New England Journal of
Medicine).
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active BAT has been reconsidered recently. This is an important
question, since previous studies on the presence of human BAT
(hBAT) and its potential effect on human energy expenditure
have failed to establish such a relationship—hampered by the
lack of noninvasive and sensitive techniques to monitor human
metabolism in vivo. Thus, to a large extent researchers have had
to resort to examining biopsies derived from major surgical proce-
dures or postmortem samples and cases of rare diseases with
enhanced levels of BAT. The availability of positron emission
tomography (PET) in the mid-1990s using the glucose tracer
2-[18F]-fluoro-D-2-deoxy-D-glucose (FDG) in combination with
computer tomography (CT) set the stage for a renewed interest
in hBAT and its role in energy expenditure (Figure 2). The first
circumstantial evidence for metabolically active BAT in humans
wasderived fromFDGPET/CTscans. Instudiesaimed atdetecting
tumors/metastasis, a confounding high symmetric uptake of FDG
was noted in the supraclavicular paracervical region and along the
thoracic spine—which was strikingly similar to what had previously
beendescribed inearlierpostmortemstudies, asdiscussedabove.
When it was found that a warm environment and b-adrenergic
antagonists appeared to diminish these signals, it was speculated
that they might bederived from bonafide hBAT.Furthersupport for
the existence of hBAT stems from reports identifying a higher
proportion of PET scans positive for this type of uptake during
the cold season. However, no direct proof was presented as to
whether regions of cold-induced FDG uptake correspond to
bona fide BAT or if this had any bearing on human metabolism.
In April last year, three papers were published in NEJM
addressing the question of the presence of hBAT in regions of
cold-induced FDG uptake, as well as its potential importance
for human energy expenditure and how it relates to other meta-
bolic parameters (Cypess et al., 2009; van Marken Lichtenbelt
et al., 2009; Virtanen et al., 2009). All three studies used FDG
CT/PET to register BAT glucose uptake (Figure 2).250 Cell Metabolism 11, April 7, 2010 ª2010 Elsevier Inc.Virtanen et al. reported a 15-fold
increase in cold-induced glucose uptake
in five healthy adult volunteers. Informa-
tion regarding the exact anatomical loca-
tion of this uptake, as determined by CT/
PET, was used by a plastic surgeon to
recover surgical biopsies from the supra-
clavicular/paracervical uptake region
(Figures 1 and 2) in three of the subjects.
WAT was also excised from the same
incision—to serve as control tissue. The
samples were examined regardingexpression of mRNAs known to constitute a BAT-specific
‘‘signature,’’ based on data from rodents. The BAT-specific
marker gene UCP1 was transcribed in the uptake region;
substantial levels of the UCP1 protein could also be detected
in Western blot experiments. In the WAT samples, neither
mRNA nor UCP1 protein could be detected. Significantly higher
levels than in the control tissue (WAT) were also found for BAT-
related mRNAs encoding iodothyronine type II (DIO2), peroxi-
some-proliferator-activated receptor g coactivator 1a (PGC1a),
PR domain-containing 16 (PRDM16), and b3-adrenergic
receptor (ADRB3). Histology showed cells with multilocular lipid
droplets, and immunohistochemistry demonstrated that such
cells also expressed UCP1 whereas WAT, as expected, did
not. Moreover, laser confocal analysis showed that the subcel-
lular expression pattern of UCP1 in cells from cold-induced
glucose uptake regions and that of a mitochondrial marker
showed a perfect match. Thus, the tissue corresponding to
cold-induced FDG uptake fulfills all relevant criteria of bona
fide BAT. Based on registered rate of FDG uptake and data
from BAT substrate preference in rodents (Ma and Foster,
1986), the authors speculated that an estimated 63 g of hBAT,
found in the supraclavicular/paracervical depot of one of the
subjects examined, could—if activated for 1 year—combust
energy equivalent to the energy content of 4.1 kg of WAT.
van Marken Lichtenbelt et al. studied 24 healthy men: 10 with
a normal body mass index (BMI) of < 25, and 14 who were over-
weight or obese with BMIR 25. BAT was found in 23 of the 24
subjects (96%), as judged by cold-induced FDG uptake using
PET. It is noteworthy that the activity of hBAT, i.e., the uptake
of tracer isotope, during cold induction was approximately
4-fold higher in the lean group than in the overweight/obese
group (p < 0.007). Furthermore, nonlinear regression analysis
showed that there was a negative correlation between BAT
activity and both BMI (r = 0.60, p = 0.002) and percentage
body fat (r =0.60, p = 0.001). There was no correlation between
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was rather narrow: between 18 and 32 years. Even though hBAT
activity was lower in the overweight/obese group, only one
subject totally lacked cold-inducible BAT. It is an open question
whether this finding reflects a higher trigger level for activation or
a lack of BAT altogether. This also suggests that in overweight/
obese individuals, activation of BAT may be of therapeutic value.
Based on PET-registered cold-induced FDG uptake (no biopsies
were taken), the authors concluded that the supraclavicular
region was the most prominent uptake region.
In the third retrospective study published by Cypress et al.,
3640 consecutive FDG PET/CT scans were studied. The scans
were performed on 1972 patients for various diagnostic reasons
(not primarily for studying hBAT). hBAT was defined as having
the density of adipose tissue according to CT and a value of
FDG uptake of at least 2.0 g/ml as determined by PET—a value
consistent with high metabolic activity. Of the 1972 patients, 106
(5.4%) were found to fulfill these criteria and were thus likely to
have significant amounts of hBAT (none of the patients were bi-
opsied). Also, in this study the cervical-supraclavicular depot
was found to be the most prominent site of FDG uptake. The
prevalence of detectable hBAT was higher in women (7.5%)
than in men (3.1%); women also had a larger mass of BAT and
higher FDG uptake. There was an inverse correlation between
the probability of detecting hBAT, in a multivariate analysis,
and (1) age (p = 0.005; in this study, patients were divided into
three groups, < 50, 50–64, and > 64 years of age), (2) outdoor
temperature at the time of the scan (p = 0.02), and (3) the use
of b-blockers (p = 0.001). Interestingly, there was also an inverse
correlation between the prevalence of detectable hBAT and BMI
in the highest age group (>64 years).
In another study (Saito et al., 2009), 56 healthy volunteers, 31
males and 25 females aged 23–65 years, were subjected to cold-
stimulated FDG uptake examination using PET. This uptake was
inversely related to BMI (p < 0.001) and to both total (p < 0.01)
and visceral (p < 0.001) fat areas, as estimated from CT images.
The study also reported seasonal variation, with increased cold-
activated FDG uptake during winter. In a similar retrospective
study of 1080 patients who underwent FDG PET/CT examina-
tion, 3.8% were judged to have significant amounts of hBAT
(Cheng et al., 2009). Major sites of uptake were ‘‘at the neck
region symmetrically’’ and paravertebral junctions. More female
patients than males had detectable BAT (p = 0.0030). They were
generally of younger age (p = 0.0001) and had a lower BMI
(p = 0.0415) than did patients with no detectable BAT uptake.
The presence of bona fide BAT in humans is also supported by
a recent study (Zingaretti et al., 2009) in which perithyroid
adipose tissue was investigated, derived from patients under-
going surgery for mainly goiter and papillary thyroid cancer.
Approximately one-third were found to have islands of BAT
within WAT in examined neck adipose tissue, as judged by
histology and the presence of UCP1-positive cells.
In a case report (Skarulis et al., 2010), a positive correlation
was found between hBAT activity and volume on the one hand
and levels of thyroid hormone on the other. A possible role of
BAT in human glucose homeostasis was suggested, since pro-
longed treatment of this patient with levothyroxine (suppressive
treatment for thyroid cancer) resulted in dramatic improvement
in insulin sensitivity, paralleled by enhanced BAT volume andactivity—in spite of extreme insulin resistance due to a mutation
in the insulin receptor gene. This observation highlights the
intriguing and potentially important possibility that activated
BAT could mediate non-insulin-dependent glucose disposal.
More studies are clearly needed to address this interesting ques-
tion—for example, to investigate other potential effects of
thyroid hormone on systemic glucose metabolism in tissues
such as skeletal muscle and WAT. The importance of thyroid
hormone for BAT function has gained support from a recent
study in mice demonstrating that the thyroid hormone
receptor-b is required for ucp1-dependent adaptive thermogen-
esis in BAT (Ribeiro et al., 2010).
Factors of study design such as age structure, sex ratio, and
type and size of study, and also if and how cold induction was
performed, are likely to contribute to the different outcomes.
Based on these reports, however, it seems reasonable to
conclude that many healthy adults, especially those of younger
age, have significant amounts of cold-inducible bona fide BAT.
It is also possible that women have a lower threshold of BAT acti-
vation, since in PET studies performed without cold exposure
prior to the scan, BAT is more readily detectable in females
(Cheng et al., 2009; Cypess et al., 2009). The largest depot
appears to be the supraclavicular/paracervical region. Also,
hBAT is metabolically active and potentially important for human
energy expenditure, as reflected by an inverse correlation
between BAT activity and BMI found in several of the studies.
It also appears that thyroid hormone can activate hBAT and
increase its mass, which is similar to the effects of catechol-
amines in cases of pheochromocytoma (Lean et al., 1986).
The Future of hBAT
The findings in support of functional hBAT are highly relevant to
both basic research and clinical medicine, since they offer the
possibility of regulating human energy expenditure. Increased
energy expenditure would be very valuable as a therapeutic
approach to obesity and obesity-related diseases such as type
2 diabetes. This could involve recruitment of brown adipocyte
progenitors and subsequent differentiation as one way of
enhancing the hBAT compartments (Crisan et al., 2008). As
has been discussed above, however, there is support for a stim-
ulatory effect on hBAT through exposure to cold, catecholamine,
and thyroid hormone. The former treatment is not very practical
and will most likely be used only by the very motivated, and in
the latter case supraphysiological concentrations of these
hormones have been associated with severe side effects.
Thus, clearly more studies are needed in order to better under-
stand the possibilities offered by hBAT. Since the availability of
hBAT always will be limited, it is of interest to find out how similar
rodent and hBAT are in terms of functionality, gene, and protein
expression. Larger prospective studies would be of great
interest; here, standardized protocols for measuring hBAT
mass and activity, and its inducibility by various external cues
such as cold exposure, would be of great value, since this would
facilitate evaluation and comparison of studies. Moreover, the
possibility of using PET in combination with tracers to study fatty
acid uptake in hBAT should be exploited to further our under-
standing of hBAT substrate preferences, since rodent studies
indicate that activated BAT relies to a great extent on fatty acid
uptake and subsequent oxidation to maintain thermogenesisCell Metabolism 11, April 7, 2010 ª2010 Elsevier Inc. 251
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dioactive methodologies to register hBAT mass and activity
would greatly facilitate future studies. Interesting possibilities
are offered by magnetic resonance imaging (MRI) techniques,
which may be useful for determination of BAT mass and tissue
blood supply, whereas exploitation of proton resonance
frequency (PRF)-based techniques for noninvasive temperature
measurements (McDannold, 2005) might be a way to monitor the
thermogenic activity of hBAT. Detailed mass-activity determina-
tions in relation to threshold of activation will eventually help
determine the role of BAT in human physiology.
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